Press release
Parkinson's Disease Pipeline Analysis: 240+ Therapies Across Multiple Stages of Development Expected to Transform the Future of Parkinson's Disease Treatment | DelveInsight
Key takeaways from the Parkinson's Disease Pipeline Report
• DelveInsight's Parkinson's disease pipeline report depicts a robust pipeline landscape with 240+ active therapies under development for Parkinson's disease treatment.
• Key Parkinson's disease companies such as Cerevance, NeuroDerm, Ltd., Annovis Bio, Alto Neuroscience, 1ST Biotherapeutics, AlzeCure, Muna Therapeutics, and others are evaluating novel therapies to improve disease management.
• Promising Parkinson's disease pipeline therapies in various stages of development include ND0612 (levodopa/carbidopa), Buntanetap, CVN424 (Solengepras), ALTO-208, FB-101, ACD-856, and others.
• The pipeline includes a broad range of innovative therapeutic approaches such as GPR6 protein inhibitors, alpha-synuclein inhibitors, dopamine receptor agonists, Trk-receptor modulators, gene therapies, cell therapies, immunotherapies, and small molecules.
Request a sample and discover the recent advances in Parkinson's disease therapies https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
What is Parkinson's Disease?
Parkinson's disease is a progressive neurodegenerative disorder caused by the loss of dopamine-producing neurons in the substantia nigra region of the brain. The disease primarily affects movement and is characterized by symptoms such as tremors, rigidity, bradykinesia, and postural instability. Parkinson's disease also involves non-motor symptoms including cognitive impairment, mood disorders, sleep disturbances, and autonomic dysfunction, significantly impacting quality of life.
The exact cause of Parkinson's disease remains unclear; however, genetic mutations, environmental exposure, mitochondrial dysfunction, α-synuclein aggregation, oxidative stress, and aging are considered major contributing factors. Diagnosis is mainly clinical and supported by neurological examination and imaging techniques such as DaTscan, PET, and SPECT scans. Current treatment approaches focus on symptom management through dopaminergic therapies, MAO-B inhibitors, COMT inhibitors, deep brain stimulation, and supportive care.
Emerging Parkinson's Disease Drug Profiles
CVN424 (Solengepras): Cerevance
CVN424 (Solengepras) is an investigational oral therapy being developed by Cerevance for the treatment of Parkinson's disease. The therapy selectively targets the GPR6 receptor and is designed to modulate the indirect pathway involved in motor control without directly affecting dopamine levels. This mechanism may help reduce motor complications commonly associated with dopaminergic therapies, including dyskinesias and motor fluctuations.
The therapy is currently being evaluated in a Phase III clinical trial for Parkinson's disease patients with motor complications. In December 2025, Cerevance presented positive Phase II results showing statistically significant reductions in OFF time and improvements in motor fluctuations with once-daily treatment.
Buntanetap: Annovis Bio
Buntanetap is an orally administered small molecule therapy currently in Phase III clinical development for Parkinson's disease. The therapy is being investigated for its potential to improve disease symptoms and address underlying neurodegenerative processes associated with Parkinson's disease progression.
The drug represents one of the advanced small molecule candidates in the Parkinson's disease pipeline landscape and highlights the growing focus on innovative neuroprotective and disease-modifying approaches.
Learn more about the novel and emerging Parkinson's disease pipeline therapies https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Recent Developments in the Parkinson's Disease Pipeline Landscape
• In September 2024, Cerevance initiated a Phase III clinical trial evaluating CVN424 in Parkinson's disease patients with motor complications.
• In November 2024, Cerevance announced dosing of the first patient in the ARISE Phase III clinical trial evaluating Solengepras as an adjunctive treatment for Parkinson's disease.
• In December 2025, Cerevance presented positive Phase II results demonstrating significant reductions in OFF time with Solengepras treatment in Parkinson's disease patients.
• In June 2025, Roche announced its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson's disease.
• In September 2025, BlueRock Therapeutics LP announced that the first patient received randomized treatment in the pivotal Phase III exPDite-2 clinical trial evaluating bemdaneprocel, an investigational cell therapy for Parkinson's disease.
• In October 2025, Arrowhead Pharmaceuticals announced the closing of a global licensing and collaboration agreement with Novartis for ARO-SNCA, an RNAi-based investigational therapy targeting alpha-synuclein for Parkinson's disease and related synucleinopathies.
Scope of the Parkinson's Disease Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Preclinical, IND, Phase I, Phase I/II, Phase II, Phase II/III, Phase III, Registration
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Nasal, Inhalation, Intrathecal, Injection, and others
• Therapeutics Assessment By Molecule Type: Small molecule, Antibody, Cell therapy, Gene therapy, Protein, Immunotherapy, Oligonucleotide, ssDNA molecule
• Key Parkinson's disease Companies: Cerevance, NeuroDerm, Ltd., Annovis Bio, Alto Neuroscience, 1ST Biotherapeutics, AlzeCure, Muna Therapeutics, and others
• Key Parkinson's disease Pipeline Therapies: ND0612 (levodopa/carbidopa), Buntanetap, CVN424 (Solengepras), ALTO-208, FB-101, ACD-856, and others
Dive deep into rich insights for new Parkinson's disease therapies, visit https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Table of Contents
1. Parkinson's Disease Pipeline Report Introduction
2. Parkinson's Disease Pipeline Report Executive Summary
3. Parkinson's Disease: Overview
4. Parkinson's Disease Pipeline Therapeutics
5. Comparative Analysis of Pipeline Products
6. Parkinson's Disease Therapeutic Assessment
7. Assessment by Route of Administration
8. Assessment by Product Type
9. Assessment by Molecule Type
10. Late-stage Products (Registration)
11. Late-stage Products (Phase III)
12. Mid-stage Products (Phase II)
13. Early-stage Products (Phase I)
14. Preclinical and Discovery Stage Products
15. Inactive Products in the Parkinson's Disease Pipeline
16. Collaborations Assessment- Licensing / Partnering / Funding
17. Unmet Needs
18. Market Drivers and Barriers
19. Future Perspectives and Conclusion
20. Analyst Views
21. Appendix
For further information on the Parkinson's disease pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Disease Pipeline Analysis: 240+ Therapies Across Multiple Stages of Development Expected to Transform the Future of Parkinson's Disease Treatment | DelveInsight here
News-ID: 4535535 • Views: …
More Releases from DelveInsight Business Research LLP
The Minimal Residual Disease Testing Market Size is estimated to grow at a CAGR …
DelveInsight's Minimal Residual Disease Testing Market Insights Report 2032 provides the current and forecast market analysis, individual leading Minimal Residual Disease Testing Companies market shares, challenges, Minimal Residual Disease Testing Market Drivers, barriers, trends, and key market Minimal Residual Disease Testing companies in the market.
To read more about the latest highlights related to the Minimal Residual Disease Testing Market, get a snapshot of the key highlights entailed in the Market…
The Digital Biomarkers Market Size is estimated to grow at a CAGR of 17.11% by 2 …
DelveInsight's Digital Biomarkers Market Insights Report 2032 provides the current and forecast market analysis, individual leading Digital Biomarkers Companies market shares, challenges, Digital Biomarkers Market Drivers, barriers, trends, and key market Digital Biomarkers companies in the market.
To read more about the latest highlights related to the Digital Biomarkers Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/digital-biomarkers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Digital Biomarkers Market Report
•…
The Artificial Tears Market Size is estimated to grow at a CAGR of 8.16% by 2032 …
DelveInsight's Artificial Tears Market Insights Report 2032 provides the current and forecast market analysis, individual leading Artificial Tears Companies market shares, challenges, Artificial Tears Market Drivers, barriers, trends, and key market Artificial Tears companies in the market.
To read more about the latest highlights related to the Artificial Tears Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/artificial-tears-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Artificial Tears Market Report
•…
The Digital Twins in Healthcare Market Size is estimated to grow at a CAGR of 28 …
DelveInsight's Digital Twins in Healthcare Market Insights Report 2032 provides the current and forecast market analysis, individual leading Digital Twins in Healthcare Companies market shares, challenges, Digital Twins in Healthcare Market Drivers, barriers, trends, and key market Digital Twins in Healthcare companies in the market.
To read more about the latest highlights related to the Digital Twins in Healthcare Market, get a snapshot of the key highlights entailed in the Market…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
QualitySolicitors Parkinson Wright invest in the future
QualitySolicitors Parkinson Wright has selected Liberate from Linetime as its business-wide legal services software platform. The Worcestershire based practice, with over 100 staff, operate from 4 offices and have a highly regarded reputation for their services including residential property, private client, family, dispute resolution and commercial. The firm also has its own estate agency.
The firm recognised that to continue delivering high quality services to its clients it needed to provide…
